Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulocuplumab + Nivolumab in SCLC and Pancreatic Cancer
NCT02472977Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2015
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of ulocuplumab in pancreatic cancer (PC), small cell lung cancer (SCLC), sponsored by Bristol Myers Squibb. Started Jul 2015; status: terminated.
02
Drugs
ulocuplumab
03
Conditions
pancreatic cancer (PC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02472977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02472977.